ART-PRO: 48-Week Results of DTG + 3TC for Maintenance of Virologic Suppression in Patients With Historical 3TC Resistance

IDWeek 2019; October 2-6, 2019; Washington, DC
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 5-6, 2019; Basel, Switzerland
17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland
This proof-of-concept study demonstrated that switching to DTG + 3TC maintained virologic control in INSTI-naive patients with historical 3TC resistance but no 3TC resistance-associated mutations in proviral DNA at baseline according to Sanger sequencing.
Format: Microsoft PowerPoint (.ppt)
File Size: 157 KB
Released: November 16, 2019

Acknowledgements

Provided by USF Health

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
ViiV Healthcare

Related Content

Clinical Care Options (CCO) presents a woman’s perspective on managing the long-term effects of HIV, antiretroviral therapy, and aging

person default Anonymous Patient Released: January 11, 2022

From Dr. Fidelia Bernice and Clinical Care Options (CCO), expert commentary on managing polypharmacy in people with HIV

Fidelia Bernice, PharmD Released: January 6, 2022

Expert faculty discuss guideline recommendations for individualizing ART, from Clinical Care Options (CCO)

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD
Program Director
Jean-Michel Molina, MD, PhD Cristina Mussini, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: December 29, 2021 Expired: December 28, 2022

Dr John Baxter and Clinical Care Options (CCO): Proviral genotyping may help to inform ART choice in patients with suppressed HIV-1 RNA, particularly if preexisting resistance is suspected

John D. Baxter, MD Released: December 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings